2025-07-25 - Analysis Report
Okay, here's the analysis of Transmedics Group Inc (TMDX) based on the provided data, presented in a structured report format.

## Transmedics Group Inc (TMDX) Analysis

Transmedics Group Inc is a medical technology company pioneering a novel approach to organ preservation for transplantation.

### 1. Performance vs. S&P 500 (VOO)

*   **TMDX Cumulative Return:** 225.58%
*   **VOO Cumulative Return:** 70.45%
*   **Absolute Performance Difference:** 156.0%
*   **Relative Performance Difference:** 61.1% (Indicates TMDX's performance is significantly higher than VOO, positioned in the higher percentile of its historical performance range.)

**Analysis:** TMDX has significantly outperformed the S&P 500 (VOO) over the analyzed period. The relative performance difference suggests that this outperformance is substantial compared to its historical volatility.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD    | Alpha    | Beta   | Cap (B) |
|------------|----------|--------|----------|--------|---------|
| 2019-2021  | -4.0%    | 63.4%  | -52.0%   | 0.0    | 0.7     |
| 2020-2022  | 140.0%   | 68.3%  | 138.0%   | 0.1    | 2.1     |
| 2021-2023  | 95.0%    | 69.4%  | 77.0%    | 0.2    | 2.7     |
| 2022-2024  | 147.0%   | 82.8%  | 121.0%   | 0.2    | 2.1     |
| 2023-2025  | 107.0%   | 82.8%  | 56.0%    | 0.5    | 3.6     |

**Analysis:**

*   **CAGR:** Shows strong growth, particularly in the 2020-2022 and 2022-2024 periods.  The CAGR remains impressive across all periods.
*   **MDD:** High Maximum Drawdown indicates significant volatility and risk.
*   **Alpha:** Consistently high positive Alpha values suggest TMDX's returns are significantly exceeding those predicted by its beta.
*   **Beta:** Low Beta values suggest TMDX is less sensitive to overall market movements. Increasing Beta in 2023-2025 could indicate a change in market sensitivity.
*   **Cap (B):** The market capitalization appears to be growing, indicating increased investor confidence.

### 2. Recent Stock Price Movement

*   **Current Price:** $106.79
*   **Previous Close:** $109.97
*   **Price Change:** -$2.89
*   **5-Day Moving Average:** $107.17
*   **20-Day Moving Average:** $119.44
*   **60-Day Moving Average:** $120.91

**Analysis:**  The recent price decline and the current price being below all moving averages indicate a short-term downward trend. The significant price change of -$2.89 suggests a noticeable recent negative event or market reaction.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3274 (Low Risk)
*   **RSI:** 26.33 (Oversold)
*   **PPO:** -1.47
*   **Hybrid Signal:** cash_69%_Sell 0.7% of holdings (4 shares - Caution - MRI:0.35)
*   **Recent (20-day) Relative Performance Change:** -2.7 (Negative, indicating short-term underperformance relative to VOO)
*   **Expected Return:** 61.7% (Long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** Indicates a relatively low-risk environment for the stock.
*   **RSI:** The oversold condition suggests that the stock might be undervalued or experiencing a temporary sell-off and could be due for a rebound.
*   **PPO:** The negative PPO value suggests the stock price is trending downwards.
*   **Hybrid Signal:** Recommends a cautious approach, advising to hold a high cash position and sell a small portion of holdings.
*   **Recent Price Change:** The recent price drop of -2.89 warrants attention, suggesting a potential negative catalyst.
*   **Expected Return:** The high expected return suggests confidence in the company's long-term prospects, exceeding the S&P 500.

### 4. Recent News & Significant Events

*   **[2025-07-25]:**  Major business developments, regulatory changes, or market events impacting Transmedics Group Inc.
*   **[2025-07-23]:** Analyst discussions regarding recent performance and outlook.
*   **[2025-07-21]:** Notable stock volatility due to recent news, earnings reports, or executive actions.
*   **[2025-07-22]:**  Market experts highlight both risks and opportunities for Transmedics Group Inc, advising investors to monitor news and company announcements.

**Analysis:**  The news indicates heightened activity and volatility surrounding TMDX, potentially driven by recent events. It's essential to investigate the specific news and announcements to understand the underlying drivers of this activity.

### 5. Recent Earnings Analysis

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |
| 2024-04-30 | 0.35 | 0.03256      |

**Analysis:** TMDX has generally exceeded EPS expectations in the recent quarters, notably with the earnings reported on 2025-05-08. However, 2024-10-28 missed the expectation. This positive trend suggests the company's financial performance is robust.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.14B  | 61.47%        |
| 2024-12-31 | $0.12B  | 59.21%        |
| 2024-09-30 | $0.11B  | 55.94%        |
| 2024-06-30 | $0.11B  | 60.59%        |
| 2024-03-31 | $0.10B  | 61.91%        |

**Capital and Profitability:**

| Quarter    | Equity   | ROE   |
|------------|----------|-------|
| 2025-03-31 | $0.27B   | 9.64% |
| 2024-12-31 | $0.23B   | 3.00% |
| 2024-09-30 | $0.21B   | 2.01% |
| 2024-06-30 | $0.19B   | 6.42% |
| 2024-03-31 | $0.16B   | 7.65% |

**Analysis:**

*   **Revenue:** Demonstrates consistent growth over the quarters.
*   **Profit Margin:** Remains strong and relatively stable, indicating efficient operations.
*   **Equity:** Shows growth, indicating increasing financial stability.
*   **ROE:** Fluctuates, but the recent increase to 9.64% is positive, suggesting improved profitability and efficient use of equity.

### 7. Overall Summary

Transmedics Group Inc (TMDX) presents a mixed picture.

*   **Positives:**
    *   Significantly outperformed the S&P 500.
    *   Strong revenue growth and high profit margins.
    *   Generally exceeding EPS expectations.
    *   High expected long-term return relative to the S&P 500.
*   **Negatives/Concerns:**
    *   High Maximum Drawdown indicates significant volatility.
    *   Recent price decline and negative short-term trends.
    *   Oversold RSI condition, which could be a buy signal or a sign of deeper issues.
    *   Cautionary hybrid signal suggesting a conservative approach.
    *   Recent news indicating potential volatility and market sensitivity.

**Recommendation:**

Based on the provided data, a cautious approach is warranted.

*   **Investigate:** Thoroughly research the recent news and events driving the stock's volatility.
*   **Monitor:** Closely monitor the stock's price action and technical indicators for signs of a reversal or continued downward trend.
*   **Consider:** The long-term expected return is attractive, but the high volatility and recent negative trends should be carefully considered before making any investment decisions. The conservative hybrid signal suggests a smaller allocation may be prudent.

